# US 2021/0332105 A1 · Compositions and methods of treating cancer with chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332105 A1
- Document ID: US20210332105A1
- Status: Published application
- Kind: A1
- Application number: 17/237,498
- Filed: 2021-04-22
- Published: 2021-10-28
- Earliest claimed: 2020-04-24
- Assignees: AstraZeneca AB
- Applicants: Astrazeneca AB
- Inventors: GORDON MOODY; MARIA LETIZIA GIARDINO-TORCHIA; MICHAEL GLEN OVERSTREET; RYAN GILBRETH
- Web page: https://patentgrep.com/patent/US20210332105A1

## CPC

- C07K 14/71: for growth factors; for growth regulators
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 14/7153: {for colony-stimulating factors [CSF]}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2836: {against CD106}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3092: {against tumour-associated mucins}
- C07K 16/32: against translation products of oncogenes
- C12N 5/0636: {T lymphocytes}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2039/844: {Liver}
- A61K 2239/21: Transmembrane domain
- A61K 2239/53: Liver
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.

## Claims

### Claim 1

An isolated nucleic acid sequence encoding
a) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen; and
b) an armoring molecule, wherein the armoring molecule counters immunosuppression of a cell in a tumor microenvironment when expressed on a surface of the cell.

### Claim 2 (depends on 1)

The isolated nucleic acid sequence of claim 1, wherein the antigen-binding domain comprises an antibody or antigen-binding fragment thereof.

### Claim 3 (depends on 2)

The isolated nucleic acid sequence of claim 2, wherein the antigen-binding domain is a Fab or a single chain variable fragment (scFv).

### Claim 4 (depends on 3)

The isolated nucleic acid sequence of claim 3, wherein the antigen-binding domain is an scFv comprising the nucleic acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34.

### Claim 5

The isolated nucleic acid sequence according to any of the preceding claims further comprising a transmembrane domain, a costimulatory domain, and a signal domain.

### Claim 6 (depends on 5)

The isolated nucleic acid sequence of claim 5, wherein the transmembrane domain comprises a CD28 transmembrane domain.

### Claim 7 (depends on 5)

The isolated nucleic acid sequence of claim 5, wherein the costimulatory domain comprises one or more of CD28, 4-1BB, CD3zeta, OX-40, ICOS, CD27, GITR, and MyD88/CD40 costimulatory domains.

### Claim 8 (depends on 5)

The isolated nucleic acid sequence of claim 5, wherein the costimulatory domain comprises one or more of CD28, 4-1BB, and CD3zeta costimulatory domains.

### Claim 9 (depends on 5)

The isolated nucleic acid sequence of claim 5, wherein the signal domain comprises a sequence encoding a CSFR2 signal peptide.

### Claim 10

The isolated nucleic acid sequence according to any of the preceding claims further comprising further comprising a hinge/spacer domain.

### Claim 11 (depends on 10)

The isolated nucleic acid sequence of claim 10, wherein the hinge/spacer domain is an IgG4P hinge/spacer.

### Claim 12 (depends on 1)

The isolated nucleic acid sequence of claim 1, wherein the armoring molecule is TGF-β receptor type 2 dominant-negative (TGFβRIIDN).

### Claim 13 (depends on 1)

The isolated nucleic acid sequence of claim 1, encoded by the nucleic acid sequence of SEQ ID NO: 46.

### Claim 14 (depends on 1)

The isolated nucleic acid of claim 1, wherein the cell surface antigen comprises one or more of CD10, CD16, CD19, CD20, CD22, CD123, CD30, CD34, CD47, CD56, CD80, CD86, CD117, CD133, CD138, CD171, CD37, CD38, CD5, CD7, CD79, 5T4, AFP, AXL, BCMA, B7H3, CDH3, CDH6, CLDN6, CLDN18, CLL-1, CMV, CS1, DLL3, DR5, FBP, GD2, GFRA1, GPA33, GPC3, IL-1-RAP, IL17RA, ITGB7, EBV, ERBB1/EGFR, ERBB2/Her-2, ERBB3, ERBB4, cMet, EGFR vIII, FAP, FOLR1, CEA, CEACAM6, EphA2, HSV-1, HSV-2, HTLV, HPV16-E6, HPV16-E7, IL13Ra2, Igκ chain, LGR5, LMP1, LeY, LRP8, MG7, MR1, NRCAM, PMEL, NKG2D ligand, PRAME, PRLR, PVR, ROR1, ROR2, SSX2, STEAP1, STEAP2, TACI, TIM3, TRBC1, VEGFR-2, EPCAM1, VCAM1, VIPR2, MAGE-A1, MAGE-A3, MAGE-A4, mesothelin (MSLN), MUC1, MUC16, NY-ESO-1, WT1, PDL1, CAIX, CD70, PSMA, and PSCA.

### Claim 15

A vector, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen and an armoring molecule, wherein the nucleic acid sequence comprises SEQ ID NO: 46.

### Claim 16 (depends on 15)

A cell comprising the vector of claim 15.

### Claim 17

A cell, comprising:
a nucleic acid sequence encoding a chimeric antigen receptor (CAR), and
a TGFβRIIDN armoring molecule expressed on a surface of the cell.

### Claim 18 (depends on 17)

The cell of claim 17, wherein the CAR comprises an antigen-binding domain, a transmembrane domain, a costimulatory domain, and a signal domain.

### Claim 19 (depends on 18)

The cell of claim 18, wherein the antigen-binding domain is a Fab or a single chain variable fragment (scFv).

### Claim 20

A cell, comprising:
an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises an antibody, Fab, or an scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL),
wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 39, and
wherein the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 40 or SEQ ID NO: 43, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41 or SEQ ID NO: 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 42 or SEQ ID NO: 45; and
a TGFβRIIDN armoring molecule.

### Claim 21 (depends on 20)

The cell of claim 20, wherein the VH comprises the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 29.

### Claim 22 (depends on 20)

The cell of claim 20, wherein the VL comprises the amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 30.

### Claim 23 (depends on 20)

The cell of claim 20, wherein the anti-GPC3 chimeric antigen receptor (CAR) and TGFβRIIDN armoring molecules comprise the amino acid sequence of SEQ ID NO: 47.

### Claim 24 (depends on 16)

The cell of claim 16, wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.

### Claim 25

A method of treating cancer, comprising:
administering to a subject in need thereof a cell, wherein the cell comprises
a) a chimeric antigen receptor (CAR) specific for a cell surface antigen, and
b) an armoring molecule, wherein the armoring molecule counters immunosuppression of the cell in a tumor microenvironment of the cancer.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cell surface antigen is one or more of CD10, CD16, CD19, CD20, CD22, CD123, CD30, CD34, CD47, CD56, CD80, CD86, CD117, CD133, CD138, CD171, CD37, CD38, CD5, CD7, CD79, 5T4, AFP, AXL, BCMA, B7H3, CDH3, CDH6, CLDN6, CLDN18, CLL-1, CMV, CS1, DLL3, DR5, FBP, GD2, GFRA1, GPA33, GPC3, IL-1-RAP, IL17RA, ITGB7, EBV, ERBB1/EGFR, ERBB2/Her-2, ERBB3, ERBB4, cMet, EGFR vIII, FAP, FOLR1, CEA, CEACAM6, EphA2, HSV-1, HSV-2, HTLV, HPV16-E6, HPV16-E7, IL13Ra2, Igκ chain, LGR5, LMP1, LeY, LRP8, MG7, MR1, NRCAM, PMEL, NKG2D ligand, PRAME, PRLR, PVR, ROR1, ROR2, SSX2, STEAP1, STEAP2, TACI, TIM3, TRBC1, VEGFR-2, EPCAM1, VCAM1, VIPR2, MAGE-A1, MAGE-A3, MAGE-A4, mesothelin (MSLN), MUC1, MUC16, NY-ESO-1, WT1, PDL1, CAIX, CD70, PSMA, and PSCA.

### Claim 27 (depends on 26)

The method of claim 26, wherein the armoring molecule is a TGFβRIIDN armoring molecule.

### Claim 28 (depends on 27)

The method of claim 27 further comprising inhibiting tumor growth, inducing tumor regression, and/or prolonging survival of the subject.

### Claim 29 (depends on 31)

The method of claim 31, wherein the cell is an autologous cell.

### Claim 30 (depends on 29)

The method of claim 29, wherein the autologous cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.

### Claim 31 (depends on 25)

The method of claim 25, wherein the cancer is a solid tumor.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cancer is hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, and/or squamous cell lung carcinoma.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cancer is hepatocellular carcinoma.

### Claim 34 (depends on 26)

The method of claim 26 further comprising administering to the subject a therapeutically effective amount of an anticancer antibody and/or a chemotherapeutic component.
